A PK-PD model for predicting the impact of age, CYP2C9, and VKORC1 genotype on individualization of warfarin therapy

被引:121
作者
Hamberg, A-K [1 ]
Dahl, M-L
Barban, M.
Scordo, M. G.
Wadelius, M.
Pengo, V.
Padrini, R.
Jonsson, E. N.
机构
[1] Uppsala Univ, Dept Med Sci, Uppsala, Sweden
[2] Univ Padua, Dept Clin & Expt Med, Padua, Italy
[3] Uppsala Univ, Dept Pharmaceut Biosci, Uppsala, Sweden
关键词
D O I
10.1038/sj.clpt.6100084
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The aim of this study was to characterize the relationship between warfarin concentrations and international normalized ratio (INR) response and to identify predictors important for dose individualization. S- and R-warfarin concentrations, INR, and CYP2C9 and VKORC1 genotypes from 150 patients were used to develop a population pharmacokinetic/pharmacodynamic model in NONMEM. The anticoagulant response was best described by an inhibitory E-MAX model, with S- warfarin concentration as the only exposure predictor for response. Delay between exposure and response was accounted for by a transit compartment model with two parallel transit compartment chains. CYP2C9 genotype and age were identified as predictors for S- warfarin clearance, and VKORC1 genotype as a predictor for warfarin sensitivity. Predicted INR curves indicate important steady-state differences between patients with different sets of covariates; differences that cannot be foreseen from early INR assessments alone. It is important to account for CYP2C9 and VKORC1 genotypes and age to improve a priori and a posteriori individualization of warfarin therapy.
引用
收藏
页码:529 / 538
页数:10
相关论文
共 24 条
[1]   Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications [J].
Aithal, GP ;
Day, CP ;
Kesteven, PJL ;
Daly, AK .
LANCET, 1999, 353 (9154) :717-719
[2]  
BEAL SL, 1994, NONMEM USERS GUIDE N
[3]  
BRECKENRIDGE A, 1974, CLIN PHARMACOL THER, V15, P424
[4]  
Gabrielsson J., 2001, Pharmacokinetic and pharmacodynamic data analysis: concepts and applications
[5]   The influence of sequence variations in factor VII, γ-glutamyl carboxylase and vitamin K epoxide reductase complex genes on warfarin dose requirement [J].
Herman, Darja ;
Peternel, Polona ;
Stegnar, Mojca ;
Breskvar, Katja ;
Dolzan, Vita .
THROMBOSIS AND HAEMOSTASIS, 2006, 95 (05) :782-787
[6]   MECHANISM OF ACTION, CLINICAL EFFECTIVENESS, AND OPTIMAL THERAPEUTIC RANGE [J].
HIRSH, J ;
DALEN, JE ;
DEYKIN, D ;
POLLER, L ;
BUSSEY, H .
CHEST, 1995, 108 (04) :S231-S246
[7]   Clinical predictors of prolonged delay in return of the international normalized ratio to within the therapeutic range after excessive anticoagulation with warfarin [J].
Hylek, EM ;
Regan, S ;
Go, AS ;
Hughes, RA ;
Singer, DE ;
Skates, SJ .
ANNALS OF INTERNAL MEDICINE, 2001, 135 (06) :393-400
[8]  
Jonsson EN, 1999, COMPUT METH PROG BIO, V58, P51, DOI 10.1016/S0169-2607(98)00067-4
[9]   A rational approach for selection of optimal covariate-based dosing strategies [J].
Jönsson, S ;
Karlsson, MO .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2003, 73 (01) :7-19
[10]   PsN-Toolkit - A collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM [J].
Lindbom, L ;
Pihlgren, P ;
Jonsson, N .
COMPUTER METHODS AND PROGRAMS IN BIOMEDICINE, 2005, 79 (03) :241-257